ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Continuous efficacy and safety of fluocinolone acetonide implant: long-term insights in diabetic macular edema patients from a portuguese hospital.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the efficacy and safety of the 0.19 mg intravitreal fluocinolone acetonide (FAc) implant over a 36-month period in patients with refractory diabetic macular edema (DME).
methodsRetrospective, single-center study including patients with refractory DME treated with the FAc implant, with outcomes assessed over 36 months. The primary endpoint was the proportion of eyes with CRT ≤ 280 μm at month 36.
resultsNinety-one eyes from 62 patients were included, with a mean baseline BCVA of 44.7 ± 18.1 ETDRS letters, CRT of 508.6 ± 176.2 μm, and DME duration of 3.6 ± 1.9 years. Eyes had received a median of 6 anti-VEGF injections (IQR, 3-13) and 2 corticosteroid injections (IQR, 1-3), and 23 (25.3%) were phakic. At month 36, 44 of 87 evaluable eyes (50.6%) had a CRT ≤ 280 μm (p < 0.0001). Mean BCVA increased by 9.4 ETDRS letters from baseline to month 36 (p < 0.0001), while mean macular volume decreased by 1.76 mm³ (p < 0.0001). Adjunctive intravitreal treatment was required in 52 eyes (57.1%), and 11 eyes (12.1%) received a second FAc implant. IOP-lowering treatment was initiated or intensified in 45 eyes (49.5%), 33 eyes (36.3%) met event-based criteria for ocular hypertension, and 8 eyes (8.8%) required glaucoma surgery. All phakic eyes at baseline (n = 23) subsequently underwent cataract surgery.
conclusionThe 0.19 mg FAc implant was associated with sustained anatomical and functional improvements over 36 months as part of the management of refractory DME. Long-term IOP monitoring remains essential.
Indexed as
Identifiers
42859197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.